In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

More precise algorithms are needed to select patients for invasive coronary testing

Dan-NICAD 2 trial presented in a Hot Line Session today at ESC Congress 2022

Coronary Artery Disease (Chronic)
Cardiac Computed Tomography
Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care


Barcelona, Spain – 28 Aug 2022: Two myocardial perfusion imaging (MPI) tests for selecting patients with suspected coronary artery disease (CAD) for invasive testing have high specificity but low sensitivity in patients who have undergone coronary computed tomography angiography (CTA), according to late breaking research presented in a Hot Line session today at ESC Congress 2022.1

“Most patients with suspected CAD referred for coronary CTA do not have obstructive disease,” said Professor Morten Bottcher of Aarhus University, Denmark. “When we find suspected obstructive disease on coronary CTA, MPI techniques are guideline-endorsed to select patients for potential revascularisation. However, our results show that while these imaging modalities identify patients with the most severe stenoses and high-risk CAD, they are less sensitive in patients with moderate stenoses and borderline or grey-zone fractional flow reserve (FFR) values who are prevalent in this setting. This means that many patients could avoid invasive testing if we apply second-line perfusion imaging. However, it also means that some patients with moderate stenoses are ‘missed’. Studies focusing on the diagnostic management of patients with moderate stenoses are therefore needed.”

Before referring patients with suspected obstructive CAD on coronary CTA to invasive coronary angiography (ICA), guidelines recommend verification of myocardial ischaemia by MPI. However, there is a gap in evidence about the performance of perfusion imaging and which perfusion modality is the most accurate in these patients. The Dan-NICAD 2 trial compared the diagnostic performance of stress MPI by 3T cardiac magnetic resonance (CMR) and 82rubidium positron emission tomography (Rb-PET) in patients with suspected obstructive stenosis on coronary CTA using ICA-FFR as the reference.

The trial included 1,732 consecutive patients with symptoms suggesting obstructive CAD who underwent coronary CTA. The average age was 59 years and 57% were men. According to coronary CTA, 445 patients (26%) had suspected stenosis (defined as >50% diameter stenosis). All 445 patients were referred for both CMR and Rb-PET in randomised order, and finally all patients underwent ICA-FFR as the reference.

A total of 372 patients completed both CMR and Rb-PET and were included in the analysis. Haemodynamically obstructive coronary artery disease was identified in 164/372 (44.1%) patients during ICA-FFR.

Sensitivities for CMR and Rb-PET were 59% (95% confidence interval [CI] 51–67%) and 64% (95% CI 56–71%), respectively (p=0.21), and specificities were 84% (95% CI 78–89%) and 89% (95% CI 84–93%), respectively (p=0.08). The positive (PPV) and negative (NPV) predictive values were similar for the two techniques: PPV for CMR 76% versus Rb-PET 79%, NPV for CMR 73% versus Rb-PET 75%. Overall accuracy was slightly higher for Rb-PET compared to CMR (78% versus 73%, respectively; p=0.03). Rb-PET correctly classified more patients with high-risk disease (left main or three-vessel disease) as abnormal compared to CMR: Rb-PET 30/31 (96.8%) versus CMR 24/31 (77.4%), p=0.03.

Both modalities had high sensitivity for severe stenoses with >70% diameter stenosis, CMR 83% (95% CI 72–91%) and Rb-PET 89% (95% CI 79–95%).

Professor Bottcher said: “Less than half of the patients (44%) with suspected CAD on coronary CTA had obstructive CAD confirmed with ICA-FFR. CMR stress and PET stress had comparably moderate sensitivities and high specificities to predict the FFR results. A perfusion test approach therefore seems safe as almost all patients with serious disease (high-grade stenoses, left main and three-vessel disease) were diagnosed. But the modest sensitivities to predict low FFR mean that there was often a discrepancy between these advanced perfusion results and the invasive FFR.”

He concluded: “The accuracy of coronary CTA needs to improve so that more patients without obstructive CAD avoid further investigations. This might be achieved through better CT image quality and perhaps by more advanced image analyses like non-invasive FFR estimation and photon counting systems. Perfusion techniques could also be improved, for example by using quantitative measurements of perfusion with CMR or 15O-water PET systems.”

 

ENDS

Notes to editor

ESC Press Office
Tel: +33 (0) 7 8531 2036
Email: press@escardio.org

Follow us on Twitter @ESCardioNews 

The hashtag for ESC Congress 2022 is #ESCCongress.

 

This press release accompanies both a presentation and an ESC press conference at ESC Congress 2022. It does not necessarily reflect the opinion of the European Society of Cardiology.

 

Funding: None.

 

Disclosures: None.

 

References and notes

1Dan-NICAD 2 will be discussed during:

2Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407–477.

 

About the European Society of Cardiology

The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.

About ESC Congress 2022

It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Barcelona and online – from 26 to 29 August. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.